AREC – Arecor Therapeutics PLC
Arecor Therapeutics (LSE:AREC) enters the second half of 2026 at an inflection point. The Cambridge-based, AIM-quoted formulation specialist has spent the past year reshaping itself into a leaner, cash-metabolic business built around two assets designed to make diabetes and obesity treatment less onerous for patients: AT278, an ultra-concentrated ultra-rapid-acting insulin, and an early-stage oral peptide delivery platform aimed initially at GLP-1 receptor agonists. Following positive US Food and Drug Administration feedback on the AT278 trial design, management has guided that the drug's pivotal next step, a Phase 2 clinical study, is anticipated to begin in the second half of 2026.
For a company valued at roughly £23m, the coming months matter more than the science alone. Arecor's stated priority for the year is to secure the best possible deal to carry AT278 into Phase 2, ideally within a broader co-development and commercialisation partnership. Whether it can convert clinical readiness and a growing roster of collaborations into funded progress, before its cash runway tightens, is the question now facing shareholders.
Company background
Arecor (LSE:AREC) is a clinical-stage biopharmaceutical company that applies its proprietary Arestat formulation technology to reformulate and enhance existing therapeutic proteins and peptides. Rather than discovering wholly new molecules, the group focuses on improving the stability, concentration and delivery of known drug classes, an approach that can shorten development timelines and reduce clinical risk relative to novel discovery.
The strategic centre of gravity is now firmly in diabetes, obesity and other cardiometabolic diseases. Over the past year the company has exited its commercial arm, Tetris Pharma, returning the relevant rights to Xeris BioPharma, to concentrate resources on its proprietary pipeline and on generating revenue from Arestat partnering. That pivot has left a smaller but more focused organisation, weighted average share count sitting at around 37.8 million, with its fortunes tied closely to a handful of programmes.
The catalyst
The event underpinning the current narrative is the advance of AT278 towards the clinic. Arecor describes it as the only ultra-concentrated, 500U/mL, ultra-rapid-acting insulin in development, positioned as an enabler for next-generation, miniaturised, longer-wear automated insulin delivery (AID) systems. Higher concentration allows smaller reservoirs and, potentially, longer wear times between refills, a meaningful reduction in day-to-day burden for insulin-dependent patients.
The asset is being co-developed with Sequel Med Tech, whose twiist AID system provides a route into the device-driven end of the market. Under a deal struck in September 2025, the two parties committed up to $1.3m each towards Phase 2-enabling work, with a stated intent to explore a broader partnership. Alongside insulin, Arecor is developing an oral delivery platform for peptides, with its first validation target a GLP-1 receptor agonist, semaglutide. A European patent has been filed on the compositions, and non-clinical pharmacokinetic studies were planned during 2026. Both threads speak to the same headline theme: lowering the treatment burden across diabetes and obesity.
Financial figures
For the year ended 31 December 2025, Arecor reported total revenue from continuing operations of £1.714m, up modestly from £1.643m a year earlier. The more striking swing came further down the statement: continuing operations delivered an operating profit of £0.932m, against a loss of £5.176m in 2024, while the group as a whole posted a profit of £0.664m compared with a £10.236m loss previously.
Much of that turnaround reflects the removal of loss-making activities and one-off financing rather than a surge in trading. A royalty financing agreement with Ligand Pharmaceuticals worth up to $11m (around £8.2m) provided $7m (about £5.2m) upfront, with a further $4m contingent on commercial milestones. Research and development spend on continuing operations was £2.694m, down from £3.041m. Cash and short-term investments stood at £6.1m at the year end, against £3.257m a year earlier, though cash used in continuing operations of £3.084m underlines that this remains a business consuming capital.
Comparison with earlier periods
Set against 2024, the accounts look transformed, but the comparison flatters the underlying picture. The prior year was weighed down by heavy losses at Tetris Pharma, £5.073m from discontinued operations, which fell to just £0.268m in 2025 as the unit wound down. Stripping out disposals and financing, the core proprietary business is still pre-profit and reliant on partnering income.
On the corporate side, Arecor added three new Arestat formulation development collaborations during the year, taking total pre-license revenue above £1m. That provides useful validation of the platform and a trickle of non-dilutive cash, but it is not yet at a scale that materially offsets development costs.
Strategy and growth drivers
Management's strategy is to de-risk AT278 through partnership rather than fund a large trial alone. The FDA's positive feedback on the Phase 2 study design, combined with the Sequel collaboration, is intended to make the asset attractive to a larger diabetes or device partner. A broader deal, converting the existing arrangement into full co-development and commercialisation, would be the clearest value driver.
The oral peptide platform offers a second, longer-dated option on the fast-growing GLP-1 market for obesity and diabetes. Success in generating a compelling non-clinical data package could open licensing conversations with far larger pharmaceutical groups. On our reading, both drivers hinge on execution and, above all, on securing external capital or partner funding.
Industry context
Arecor is operating in one of the most contested areas of pharmaceuticals. The GLP-1 boom has drawn in the sector's largest players, and automated insulin delivery is advancing rapidly as devices shrink and integrate more tightly with algorithms. That backdrop cuts both ways: it creates obvious partnering demand for enabling technologies such as ultra-concentrated insulin, but it also places Arecor alongside far better-resourced competitors developing their own next-generation formulations and oral peptides.
The company sought to capitalise on this appetite by presenting at high-profile events during the summer, including the American Diabetes Association Scientific Sessions in New Orleans in early June and the BIO International Convention in San Diego later that month, both explicitly aimed at advancing partnering discussions.
Key risks
The central risk is funding. Management indicated that current cash supports operations into May 2027, with additional funding required by the second quarter of 2027, and the accounts carried a material uncertainty in relation to going concern. For a micro-cap, a dilutive raise or a delayed partnership would weigh heavily on sentiment.
Clinical and commercial risks compound this. AT278 has yet to enter Phase 2, and positive earlier pharmacokinetic data does not guarantee success in a device setting. The oral peptide programme remains pre-clinical and unproven. Partnering income is lumpy, and much of the reported 2025 profit stemmed from financing and disposals rather than recurring trade. The shares, changing hands around 61.5p in early August and trading below their 50-day and 200-day averages, reflect a market still awaiting hard catalysts.
Milestones to watch
The nearest and most consequential milestone is the initiation of the AT278 Phase 2 study, guided for the second half of 2026, and any announcement of a broadened partnership to fund it. Investors should also watch for the emergence of non-clinical pharmacokinetic data from the oral GLP-1 programme, further Arestat collaboration wins, and receipt of the contingent Ligand milestone payments. Progress on any funding arrangement ahead of the 2027 runway constraint will be closely scrutinised.
Conclusion
Arecor has emerged from a difficult restructuring leaner, more focused and, on paper, profitable, but the headline figures owe more to disposals and financing than to a self-sustaining business. Its pipeline speaks directly to two of the largest themes in modern medicine, reducing the burden of insulin therapy and improving delivery of GLP-1 drugs, and a clinically de-risked lead asset gives it a credible seat at the partnering table.
The counterweight is a finite cash runway and an acknowledged going-concern uncertainty that keep the investment case firmly binary. On our reading, the next twelve months will be defined less by the science, which management has advanced steadily, than by whether Arecor can translate that progress into a funded Phase 2 and a partner willing to back it.






Please wait processing your request...